Sector News

J&J sells Cordis to Cardinal for $1.94bn

March 3, 2015
Life sciences
Healthcare giant Johnson & Johnson is selling its vascular med tech group Cordis to US drug distributer Cardinal Health for $1.94 billion, severing its ties with the field.
 
Cordis booked annual sales last year of around $780 million, split between cardiology and endovascular products, and Cardinal says it expects its acquisition to add more than $0.20 in earnings per share from fiscal 2017.
 
The move will significantly boost interventional cardiology and endovascular products, such as heart stents and catheters, Cardinal can offer hospitals and physicians, in line with a broader strategy of increasing its portfolio of medical device products.
 
“With an ageing population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best way to bring quality care to their patients in the most cost-effective way. The acquisition of Cordis reinforces our strategic position to address this need and strengthens an important growth driver in the Cardinal Health portfolio,” said chief executive George Barrett, further explaining the decision.
 
The deal, which Cardinal expects to fund with a combination of $1.0 billion in new senior unsecured notes and the remainder with existing cash, is expected to close in the US and key non-US countries towards the end of this year.
 
By Selina McKee
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend